Laurion Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Laurion Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,008	Closed	-$1.24M	–	933
2020 Q4	$1.24M	Buy	+10,008	New	+$1.32M	0.01%	389
2020 Q3	–	Sell	-8,641	Closed	-$1.35M	–	1223
2020 Q2	$1.35M	Buy	+8,641	New	+$1.31M	0.02%	365
2018 Q2	–	Sell	-161,139	Closed	-$3.31M	–	1657
2018 Q1	$3.31M	Sell	161,139 -356,952	-69%	-$9.19M	0.03%	476
2017 Q4	$14.7M	Buy	+518,091	New	+$14.5M	0.07%	266

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Laurion Capital Management's RETA Position: Q1 2021 in Review

Laurion Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2021, closing a stake of 10,008 shares — an estimated $1.24M sold.

Laurion Capital Management first reported a position in RETA in Q4 2017 and held it in 4 quarters. The position peaked at $14.7M in Q4 2017. 201 funds tracked by Wall St. Rank hold RETA as of Q1 2021.

Laurion Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
Laurion Capital Management sold 10,008 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2021, an estimated $1.24M.
Laurion Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 4 quarters.
Laurion Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $14.7M in Q4 2017.
201 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2021.

Based on Laurion Capital Management's 13F filing for Q1 2021, filed 14 May 2021.